Clinical trial
Vaccine Therapy in Treating Patients With Stage IV Melanoma
NCT00042783 · SWOG Cancer Research Network, Other · Completed
Key facts
| NCT number | NCT00042783 |
|---|---|
| Title | Vaccine Therapy in Treating Patients With Stage IV Melanoma |
| Official title | A Phase II Trial Of A D1/3-MAGE3-HIS Fusion Protein (NSC-719274) With Adjuvant SBAS02B (NSC-719275) For Patients With Stage IV, M1a or M1b Metastatic Melanoma |
| Lead sponsor | SWOG Cancer Research Network, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Biological |
| Interventions | D1/3-MAGE-3-His fusion protein, SB-AS02B adjuvant |
| Start date | Sep 1, 2002 |
| Completion | Mar 1, 2006 |
| First posted | Jan 27, 2003 |
| Last update posted | Jun 24, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: